U.S. FDA puts Blueprint Medicines' cancer drug trial on partial hold

Blueprint Medicines

10/02/2023 13:10

Feb 10 (Reuters) - Blueprint Medicines Corp  BPMC.O 
said on Friday the U.S. drugs regulator had put an early-stage
trial of its experimental cancer drug on partial hold due to
safety concerns. 
    The drug developer said visual problems had been reported in
a limited number of patients, prompting the hold on enrollment. 
 (Reporting by Pratik Jain in Bengaluru; Editing by Dhanya Ann
Thoppil)
 ((Pratik.Jain@thomsonreuters.com;))